Full-Time

Associate Director

Clinical Supply Chain

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$138.5k - $188.5k/yr

+ Equity Grants + Bonus + Incentive Compensation

Remote in USA

Remote

Remote within the United States.

Category
Operations & Logistics (1)
Required Skills
Inventory Management

Get referred to BeOne

See people who can refer or advise you

Requirements
  • Bachelor or Master Degree in Business Administration, Operations Management, or similar education required
  • 8+ years of progressive experience in Supply Chain preferably within the biotech, pharmaceutical, CRO, industry
  • People leadership and development experience preferred
  • Knowledge of clinical supply best practices, IRT systems, and experience working within a GxP environment
Responsibilities
  • Represent the Clinical Supply Chain on cross functional project meetings such as; Clinical Demand and Operations Planning (CD&OP), Development Core Teams (DCT)
  • Represent on Clinical Study Teams (CST) and program development teams and provide a high service level to internal stakeholders (e.g. Clinical Operations, Regulatory, Quality, CMC)
  • Provide managerial support to employees with the overall responsibility of leading, training, and mentoring for effective performance
  • Work with Clinical Operations to understand clinical demand requirements and ensure alignment with study teams to supply plans and timelines
  • Develops strategies for inventory plans and ensures production schedules for clinical trial materials are on track
  • Monitor and oversee schedule adherence of production schedules and make course corrections if needed
  • Oversee GMP inventory throughout the supply chain, develop inventory reports, manage upcoming expiry, and ensure drug accountability
  • Oversee daily activities for finished goods FG label & pack CMOs and distribution vendors with internal stakeholders
  • Responsible for investigation of exceptions to determine root causes, implement CAPAs and drive closure
  • Ensure label text and proofs are in accordance with applicable rules, regulations, product specifications, and clinical study protocol(s)
  • Develops IRT supply strategy and oversee ongoing supply activities in system and inputs for system builds
  • Develop supply strategies to maximize supply efficiency, minimize waste while identifying risk and develop risk mitigation plans
  • Prepare and manage the Clinical Supply Chain functional budget for studies/programs
  • Lead cross functional projects and process improvements related to drug supply
  • Create and/or revise process documents such as Standard Operating Procedures
  • Additional responsibilities as required
  • Oversee supervision of direct reports and mentoring as part of supervisory responsibilities
Desired Qualifications
  • People leadership and development experience preferred

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BRUKINSA and sonrotoclax can expand fixed-duration CLL treatment standards.
  • BGB-43395 and BG-C9074 deepen breast-cancer pipeline optionality.
  • Q1 2026 revenue reached $1.5 billion, supporting broader R&D investment.

What critics are saying

  • Revenue still depends heavily on BRUKINSA, exposing the company to concentration risk.
  • Solid-tumor programs remain early-stage, with limited efficacy and tolerability data.
  • Insider stock sales can pressure sentiment despite the 10b5-1 plan.

What makes BeOne unique

  • Global oncology platform spans hematology, immunology, and solid tumors.
  • BRUKINSA anchors a leading hematology franchise across multiple approved markets.
  • Large global trial network enables faster, more cost-efficient clinical development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-7%

1 year growth

-9%

2 year growth

-3%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...